Maybe MT resigned before shareholders realised he may mislead them.
Announcement 16 February
This represents a significant milestone for the company as it plans to undertake an adaptive phase 2/3 clinical study in Q2 2024
21 February
Data will be used to support the ODD application and open an IND with US FDA to commence an adaptive 2/3 study in H1 CY 2024
14 March
PAA remains on track to commence pivotal phase 2/3 study for MND/ALS in H1 CY 2024
Then these two statements hidden at the bottom of announcement 16 and 18 April under about PharmAust
PAA anticipates commencing enrolment in the pivotal registration adaptive phase 2/3 clinical study in H2 2024
Maybe MT resigned before shareholders realised he may mislead...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.90M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.0¢ | 20.0¢ | $191.1K | 906.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1300 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 9563 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
21.0¢ |
Change
0.000 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 22.0¢ | 22.5¢ | 20.5¢ | 533029 | ||
| Last updated 15.54pm 03/05/2024 ? | |||||
| PAA (ASX) Chart |